Home › Research › Biomarkers
PET approaches for diagnosis of dementia
Ishii K.. AJNR. American journal of neuroradiology, 2013-08-14
Topic: Risk, prevention and care in population studies
There is increasing use of neuroimaging modalities, including PET, for diagnosing dementia. For example, FDG-PET demonstrates hypometabolic regions in the posterior cingulate gyri, precuneus, and parietotemporal association cortices, while amyloid PET indicates amyloid deposition in Alzheimer disease and mild cognitive impairment due to Alzheimer disease. Furthermore, the use of combination PET with structural MR imaging can improve the diagnostic accuracy of dementia. In other neurodegenerative dementias, each disease exhibits a specific metabolic reduction pattern. In dementia with Lewy bodies, occipital glucose metabolism is decreased, while in frontotemporal dementia, frontal and anterior temporal metabolism is predominantly decreased. These FDG-PET findings and positive or negative amyloid deposits are important biomarkers for various neurodegenerative dementias.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ishii, K. (2014). PET approaches for diagnosis of dementia. AJNR. American journal of neuroradiology. https://doi.org/10.3174/ajnr.a3695
Vancouver
Ishii K. PET approaches for diagnosis of dementia. AJNR. American journal of neuroradiology. 2014. doi:10.3174/ajnr.a3695. PMID: 23945233.
BibTeX
@article{ishii2014-23945233,
author = {Ishii, K.},
title = {{PET approaches for diagnosis of dementia}},
journal = {AJNR. American journal of neuroradiology},
year = {2014},
doi = {10.3174/ajnr.a3695},
pmid = {23945233},
url = {https://doi.org/10.3174/ajnr.a3695}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- For example, FDG-PET demonstrates hypometabolic regions in the posterior cingulate gyri, precuneus, and parietotemporal association cortices, while amyloid PET indicates amyloid deposition in Alzheimer disease and mild cognitive impairment due to Alzheimer disease.
- Furthermore, the use of combination PET with structural MR imaging can improve the diagnostic accuracy of dementia.
- In other neurodegenerative dementias, each disease exhibits a specific metabolic reduction pattern.
- In dementia with Lewy bodies, occipital glucose metabolism is decreased, while in frontotemporal dementia, frontal and anterior temporal metabolism is predominantly decreased.
- These FDG-PET findings and positive or negative amyloid deposits are important biomarkers for various neurodegenerative dementias.
Why it matters
This review describes how FDG-PET and amyloid PET show different patterns in Alzheimer disease and other dementias and can improve diagnostic accuracy when combined with structural MRI. It is about diagnosis and does not test any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (AJNR. American journal of neuroradiology) |
| Journal's citation record | 2 / 4 | American Journal of Neuroradiology: journal h-index 182 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 148 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.6 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 4 / 6 | Cited 8.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 2 / 4 | Cited 22 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Kazunari Ishii: h-index 53 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Kindai University Hospital: institution h-index 203 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23945233) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Biomarkers
Also tagged “prevalence”
1,223 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,223 tagged studies.